D.A. Davidson & CO. Has $2.08 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

D.A. Davidson & CO. reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,154 shares of the pharmaceutical company’s stock after selling 321 shares during the quarter. D.A. Davidson & CO.’s holdings in Vertex Pharmaceuticals were worth $2,076,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Highline Wealth Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the 3rd quarter worth $27,000. Dunhill Financial LLC lifted its position in Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 24 shares during the last quarter. Brown Lisle Cummings Inc. bought a new stake in Vertex Pharmaceuticals in the 4th quarter worth approximately $30,000. Legacy Investment Solutions LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Finally, Truvestments Capital LLC bought a new stake in Vertex Pharmaceuticals in the third quarter valued at approximately $35,000. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Trading Up 0.8 %

Shares of Vertex Pharmaceuticals stock opened at $484.24 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a market capitalization of $124.35 billion, a P/E ratio of -220.11, a P/E/G ratio of 2.07 and a beta of 0.41. The business has a 50 day moving average price of $436.05 and a 200 day moving average price of $460.70.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.58 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the completion of the transaction, the executive vice president now directly owns 64,021 shares of the company’s stock, valued at $29,438,776.43. This represents a 0.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.20% of the company’s stock.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 11th. UBS Group increased their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Truist Financial upped their price target on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. BMO Capital Markets lowered their price target on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a report on Friday, December 20th. Finally, Morgan Stanley increased their target price on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a report on Tuesday, February 11th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $505.61.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.